{"id":13965,"date":"2005-07-04T00:00:00","date_gmt":"2005-07-04T04:00:00","guid":{"rendered":"https:\/\/icesontario.wpengine.com\/publications\/research-papers\/uptake-and-outcomes-associated-with-cyclooxgenase-cox-2-inhibitors-in-ontarios-elderly\/"},"modified":"2023-06-14T08:53:06","modified_gmt":"2023-06-14T12:53:06","slug":"uptake-and-outcomes-associated-with-cyclooxgenase-cox-2-inhibitors-in-ontarios-elderly","status":"publish","type":"research_report","link":"https:\/\/www.ices.on.ca\/fr\/publications\/research-reports\/uptake-and-outcomes-associated-with-cyclooxgenase-cox-2-inhibitors-in-ontarios-elderly\/","title":{"rendered":"Uptake and Outcomes Associated with Cyclooxgenase (COX-2) Inhibitors in Ontario&rsquo;s Elderly"},"content":{"rendered":"<p>Many clinical and policy questions related to outcomes and costs have arisen following the recent introduction of a group of nonsteroidal anti-inflammatory drugs (NSAIDs), selective cyclooxygenase (COX-2) inhibitors, to drug formularies.<\/p>\n<p>The purpose of this report is to:<\/p>\n<ul>\n<li>Examine clinically relevant outcomes associated with COX-2 inhibitors relative to nonselective NSAIDS among an elderly population;<\/li>\n<li>Examine changes in population costs to the healthcare system and clinical outcome rates following the introduction of COX-2 inhibitors to the Ontario Drug Benefit formulary; and<\/li>\n<li>Examine basic adherence rates associated with COX-2 inhibitors and nonselective NSAIDS among an elderly population.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Many clinical and policy questions related to outcomes and costs have arisen following the recent introduction of a group of nonsteroidal anti-inflammatory drugs (NSAIDs), selective cyclooxygenase (COX-2) inhibitors, to drug formularies. The purpose of this report is to: Examine clinically relevant outcomes associated with COX-2 inhibitors relative to nonselective NSAIDS among an elderly population; Examine [&hellip;]<\/p>\n","protected":false},"template":"","migration-helper-automated":[],"topic":[],"class_list":["post-13965","research_report","type-research_report","status-publish","hentry"],"acf":{"citation":"Mamdani M, Kopp A, Laupacis A, Rochon PA, Juurlink DN, Anderson GM, Naglie G, Austin PC, Lee DS, Stukel T&#xa0;. July 2005","source_url":"","ices_scientist":[1325,1293,1340,1282,1382,1385,1290,1372],"site":[],"research_program":[],"news_release":[],"journal_article":[],"atlas":null,"research_report":null,"infographic":[],"video":[],"downloads":[{"title":"Full Report","description":"","file":19148}],"links":null,"sitecore_item_id":"68502D8D-C6E7-4DFB-BF08-643A70AAA725","sitecore_item_name":"Uptake-and-outcomes","sitecore_field_values":"{\n  \"Title\": \"Uptake and Outcomes Associated with Cyclooxgenase (COX-2) Inhibitors in Ontario's Elderly\",\n  \"Short title\": \"Uptake and Outcomes\",\n  \"Teaser image\": \"<image mediaid=\"{E253268D-1CE6-4DC7-84F9-ED9CC430DAA0}\" mediapath=\"\/Images\/Atlases-and-Reports\/Atlases-and-Reports-th\/2005\/UptakeandoutcomesassociatedwithcyclooxgenaseCOX2inhibitorsinOntarioselderly\" src=\"~\/media\/E253268D1CE64DC784F9ED9CC430DAA0.ashx\" alt=\"Uptake and Outcomes Associated with Cyclooxgenase (COX-2) Inhibitors in Ontario's Elderly\" height=\"\" width=\"\" hspace=\"\" vspace=\"\" \/>\",\n  \"Image\": \"<image mediaid=\"{E253268D-1CE6-4DC7-84F9-ED9CC430DAA0}\" mediapath=\"\/Images\/Atlases-and-Reports\/Atlases-and-Reports-th\/2005\/UptakeandoutcomesassociatedwithcyclooxgenaseCOX2inhibitorsinOntarioselderly\" src=\"~\/media\/E253268D1CE64DC784F9ED9CC430DAA0.ashx\" alt=\"Uptake and Outcomes Associated with Cyclooxgenase (COX-2) Inhibitors in Ontario's Elderly\" height=\"\" width=\"\" hspace=\"\" vspace=\"\" \/>\",\n  \"Citation\": \"<p>Mamdani M, Kopp A, Laupacis A, Rochon PA, Juurlink DN, Anderson GM, Naglie G, Austin PC, Lee DS, Stukel T&nbsp;. July 2005 <\/p>\",\n  \"Abstract\": \"<p>Many clinical and policy questions related to outcomes and costs have arisen following the recent introduction of a group of nonsteroidal anti-inflammatory drugs (NSAIDs), selective cyclooxygenase (COX-2) inhibitors, to drug formularies.<\/p>rn<p>The purpose of this report is to:<\/p>rn<ul>rn    <li>Examine clinically relevant outcomes associated with COX-2 inhibitors relative to nonselective NSAIDS among an elderly population;<\/li>rn    <li>Examine changes in population costs to the healthcare system and clinical outcome rates following the introduction of COX-2 inhibitors to the Ontario Drug Benefit formulary; and<\/li>rn    <li>Examine basic adherence rates associated with COX-2 inhibitors and nonselective NSAIDS among an elderly population.<\/li>rn<\/ul>\",\n  \"Keywords\": \"{9BFE8304-A69B-4322-82EF-4930556FD32C}|{53FC76BF-785B-4A1C-805E-1E03634BE9CF}|{F98C94A2-8572-460A-BAB2-70B54560A83C}\",\n  \"Availability\": \"{E4EB0DEA-E2E7-42A0-9198-F55356984A71}\",\n  \"Copyright Text\": \"ICES\",\n  \"Downloads\": \"{9530FAEA-8CAE-40C1-8CAD-68D61117EC64}\",\n  \"ICES Scientists\": \"{F2F916BC-2EE9-4C65-BCAB-086ED6BB971A}|{83920C20-06BE-4C6B-9FA7-06B69A509A24}|{14B76C34-3A35-4785-86C4-9B1633E28765}|{5268F1B0-EB3E-4577-93DF-3C70C9399847}|{38899D1B-38E7-4517-8DA3-0BDDF1F9944D}|{7D498E8B-5801-4F9E-AC41-11ED50F3C34E}|{CEEE13AD-C7DE-455F-ACF8-AAD7D27BB178}|{A0978F87-1C10-4E62-A833-89616146CA59}\",\n  \"Posted Date\": \"20050704T000000\",\n  \"Read Online Link\": \"<link url=\"..\/..\/flip-publication\/uptake-outcomes-associated-cyclooxgenase\/index.html\" linktype=\"external\" id=\"\" \/>\"\n}","previous_url":"https:\/\/www.ices.on.ca\/Publications\/Atlases-and-Reports\/2005\/Uptake-and-outcomes"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ICES | Uptake and Outcomes Associated with Cyclooxgenase (COX-2) Inhibitors in Ontario&#039;s Elderly<\/title>\n<meta name=\"description\" content=\"Many clinical and policy questions related to outcomes and costs have arisen following the recent introduction of a group of nonsteroidal\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/publications\/research-reports\/uptake-and-outcomes-associated-with-cyclooxgenase-cox-2-inhibitors-in-ontarios-elderly\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ICES | Uptake and Outcomes Associated with Cyclooxgenase (COX-2) Inhibitors in Ontario&#039;s Elderly\" \/>\n<meta property=\"og:description\" content=\"Many clinical and policy questions related to outcomes and costs have arisen following the recent introduction of a group of nonsteroidal\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/publications\/research-reports\/uptake-and-outcomes-associated-with-cyclooxgenase-cox-2-inhibitors-in-ontarios-elderly\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T12:53:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/research-reports\\\/uptake-and-outcomes-associated-with-cyclooxgenase-cox-2-inhibitors-in-ontarios-elderly\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/research-reports\\\/uptake-and-outcomes-associated-with-cyclooxgenase-cox-2-inhibitors-in-ontarios-elderly\\\/\",\"name\":\"ICES | Uptake and Outcomes Associated with Cyclooxgenase (COX-2) Inhibitors in Ontario's Elderly\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2005-07-04T04:00:00+00:00\",\"dateModified\":\"2023-06-14T12:53:06+00:00\",\"description\":\"Many clinical and policy questions related to outcomes and costs have arisen following the recent introduction of a group of nonsteroidal\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/research-reports\\\/uptake-and-outcomes-associated-with-cyclooxgenase-cox-2-inhibitors-in-ontarios-elderly\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/research-reports\\\/uptake-and-outcomes-associated-with-cyclooxgenase-cox-2-inhibitors-in-ontarios-elderly\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/research-reports\\\/uptake-and-outcomes-associated-with-cyclooxgenase-cox-2-inhibitors-in-ontarios-elderly\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Reports\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/research-reports\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Uptake and Outcomes Associated with Cyclooxgenase (COX-2) Inhibitors in Ontario&#8217;s Elderly\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ICES | Uptake and Outcomes Associated with Cyclooxgenase (COX-2) Inhibitors in Ontario's Elderly","description":"Many clinical and policy questions related to outcomes and costs have arisen following the recent introduction of a group of nonsteroidal","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/publications\/research-reports\/uptake-and-outcomes-associated-with-cyclooxgenase-cox-2-inhibitors-in-ontarios-elderly\/","og_locale":"fr_FR","og_type":"article","og_title":"ICES | Uptake and Outcomes Associated with Cyclooxgenase (COX-2) Inhibitors in Ontario's Elderly","og_description":"Many clinical and policy questions related to outcomes and costs have arisen following the recent introduction of a group of nonsteroidal","og_url":"https:\/\/www.ices.on.ca\/fr\/publications\/research-reports\/uptake-and-outcomes-associated-with-cyclooxgenase-cox-2-inhibitors-in-ontarios-elderly\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2023-06-14T12:53:06+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/research-reports\/uptake-and-outcomes-associated-with-cyclooxgenase-cox-2-inhibitors-in-ontarios-elderly\/","url":"https:\/\/www.ices.on.ca\/fr\/publications\/research-reports\/uptake-and-outcomes-associated-with-cyclooxgenase-cox-2-inhibitors-in-ontarios-elderly\/","name":"ICES | Uptake and Outcomes Associated with Cyclooxgenase (COX-2) Inhibitors in Ontario's Elderly","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2005-07-04T04:00:00+00:00","dateModified":"2023-06-14T12:53:06+00:00","description":"Many clinical and policy questions related to outcomes and costs have arisen following the recent introduction of a group of nonsteroidal","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/publications\/research-reports\/uptake-and-outcomes-associated-with-cyclooxgenase-cox-2-inhibitors-in-ontarios-elderly\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/publications\/research-reports\/uptake-and-outcomes-associated-with-cyclooxgenase-cox-2-inhibitors-in-ontarios-elderly\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/research-reports\/uptake-and-outcomes-associated-with-cyclooxgenase-cox-2-inhibitors-in-ontarios-elderly\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Research Reports","item":"https:\/\/www.ices.on.ca\/fr\/publications\/research-reports\/"},{"@type":"ListItem","position":3,"name":"Uptake and Outcomes Associated with Cyclooxgenase (COX-2) Inhibitors in Ontario&#8217;s Elderly"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_report\/13965","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_report"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/research_report"}],"acf:post":[{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1372"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1290"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1385"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1382"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1282"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1340"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1293"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1325"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=13965"}],"wp:term":[{"taxonomy":"migration-helper-automated","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-automated?post=13965"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/topic?post=13965"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}